Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
---|---|---|---|---|---|---|---|---|---|---|---|---|
184B5 | NM | Basal | Bromopyruvic acid | Hexokinase II | Metabolism | 0.267 | uM | 12979.177 | 0.0006 | -1.0000 | 0.5647 | |
184B5 | NM | Basal | Bromopyruvic acid | Hexokinase II | Metabolism | 6.67 | uM | 12979.177 | 0.0007 | -1.0000 | 0.5647 | |
HCC1395 | TNBC | Basal B | CGC-11047 | Polyamine analogue | 5000 | uM | 9258.026 | 0.0020 | -1.0000 | 0.5632 | ||
BT-474 | HER2amp | Luminal | CGC-11047 | Polyamine analogue | 5000 | uM | 9163.026 | 0.0078 | -1.0000 | 0.3738 | ||
UACC-812 | HER2amp | Luminal | CGC-11047 | Polyamine analogue | 5000 | uM | 10151.034 | 0.0277 | -1.0000 | 0.3226 | ||
HCC2185 | TNBC | Luminal | Carboplatin | DNA cross-linker | DNA cross-linker | 1350 | uM | 9421.021 | 0.0148 | -1.0000 | 0.3726 | |
600MPE | HR+ | Luminal | Bromopyruvic acid | Hexokinase II | Metabolism | 1.33 | uM | 13091.177 | 0.0005 | -1.0000 | 0.7004 | |
600MPE | HR+ | Luminal | Bromopyruvic acid | Hexokinase II | Metabolism | 33.3 | uM | 13091.177 | 0.0005 | -1.0000 | 0.7004 | |
184B5 | NM | Basal | Chloroquine | 66.5 | uM | 12979.177 | 0.0006 | -1.0000 | 0.5647 | |||
MDA-MB-361 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 66.7 | uM | 12379.165 | 0.0063 | -1.0000 | 0.3550 | |
600MPE | HR+ | Luminal | Bromopyruvic acid | Hexokinase II | Metabolism | 6.67 | uM | 13091.177 | 0.0005 | -1.0000 | 0.7004 | |
MDA-MB-361 | HER2amp | Luminal | Afatinib | EGFR/HER2 | ErbB | 13.3 | uM | 12379.165 | 0.0149 | -1.0000 | 0.3550 | |
HCC1187 | TNBC | Basal A | Cisplatin | DNA cross-linker | DNA cross-linker | 250 | uM | 7811.017 | 0.0060 | -1.0000 | 0.3604 | |
MDA-MB-361 | HER2amp | Luminal | Bromopyruvic acid | Hexokinase II | Metabolism | 33.3 | uM | 12989.177 | 0.0004 | -1.0000 | 0.3765 | |
184B5 | NM | Basal | Bromopyruvic acid | Hexokinase II | Metabolism | 1.33 | uM | 12979.177 | 0.0009 | -1.0000 | 0.5647 | |
MDA-MB-361 | HER2amp | Luminal | Bromopyruvic acid | Hexokinase II | Metabolism | 1.33 | uM | 12989.177 | 0.0017 | -1.0000 | 0.3765 | |
HCC202 | HER2amp | Luminal | 17-AAG | HSP90 | HSP90 | 100 | uM | 9402.037 | 0.0159 | -1.0000 | 0.3763 | |
SUM1315MO2 | TNBC | Basal B | 17-AAG | HSP90 | HSP90 | 100 | uM | 9797.037 | 0.0118 | -1.0000 | 0.3871 | |
MDA-MB-361 | HER2amp | Luminal | Bromopyruvic acid | Hexokinase II | Metabolism | 6.67 | uM | 12989.177 | 0.0034 | -1.0000 | 0.3765 | |
BT-474 | HER2amp | Luminal | Bromopyruvic acid | Hexokinase II | Metabolism | 33.3 | uM | 13125.177 | 0.0001 | -1.0000 | 0.8991 | |
HCC1187 | TNBC | Basal A | (Z)-4-Hydroxytamoxifen | ESR1 | 167 | uM | 7811.044 | 0.0124 | -1.0000 | 0.3073 | ||
184B5 | NM | Basal | Bromopyruvic acid | Hexokinase II | Metabolism | 33.3 | uM | 12979.177 | 0.0006 | -1.0000 | 0.5647 | |
HCC1187 | TNBC | Basal A | 17-AAG | HSP90 | HSP90 | 100 | uM | 7811.04 | 0.0158 | -1.0000 | 0.3921 | |
MCF12A | NM | Basal B | Doxorubicin | TOP2 | TOP | 92 | uM | 7491.078 | 0.0003 | -1.0000 | 0.7238 | |
MB 157 | Unknown | Unknown | Doxorubicin | TOP2 | TOP | 92 | uM | 9039.078 | 0.0002 | -1.0000 | 0.6306 |